BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast. Credit: Thomas Breen Subscribe now Already have an account? Sign in.
